changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact firstname.lastname@example.org
Discover how absorbed radiation dose to tumor maximises necrosis without compromising patient safety 3-6, 13, 45, 46
Stop Exposing Yourself to Unnecessary Radiation
Simplicit90Y™ is customised, easy-to-use dosimetry software developed for improving 90Y SIRT workflow and personalising dosimetry.
Some liver cancer treatments work through their embolic properties. TheraSphere™ utilises radiation as its primary mode of action to destroy tumour tissue.1 The high activity of glass microspheres makes TheraSphere™ microembolic and preserves normal parenchymal flow since fewer microspheres are needed to achieve the desired absorbed dose.1,3,5,7,11,45
High absorbed dose coverage should be the goal of treatment with radioembolisation. Influenced by the combined effects of microsphere coverage and administered activity, a greater absorbed dose to tumour with TheraSphere™ leads to improved outcomes above certain absorbed dose thresholds without compromising patient safety.1,2,5,6,39,43
TheraSphere™ offers the flexibility to optimise absorbed dose to the tumor to meet individual patient treatment goals in both the curative and palliative settings. This enables clinical utility for downstaging, bridge to transplant, radiation segmentectomy and portal vein thrombosis.8,9,40,44
TheraSphere™ yttrium-90 glass microspheres deliver a targeted radiation dose to the tumour whilst minimising exposure to healthy tissue with mild to moderate side effects.15
High activity TheraSphere™ glass microspheres deliver greater tumour absorbed dose coverage while resin has greater microsphere coverage.43
Total dose to the liver does not exceed 150 Gy.
Arizona Patients Successfully Receive th...
Recommended Cash Offer for BTG plc by Bo...
BTG plc: Interim Results 2018
OPTALYSE PE Results Presented at Society...
Healthcare Player BTG on lookout for acq...
NICE highlights potential role of TheraS...